Search Medical Condition
Please enter condition
Please choose location from dropdown

Zhenzhou, China Clinical Trials

A listing of Zhenzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (277) clinical trials

REALM China Extension Study

The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study

Phase N/A

0.0 miles

Learn More »

Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency

To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG Somatropin Injection.

Phase

0.0 miles

Learn More »

A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence

This study takes "Rate of stone recurrence" as primary outcome measure, by random, blank control, and multicenter clinical trial design method, assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis formation or recurrence, provide evidence for drug re-registration, and observe its efficacy on Urinary calculi such as …

Phase

0.0 miles

Learn More »

Multi-center Single Arm Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

DONATE study is a multi-center, prospective cohort, single arm, observational study to be performed in 3000 Chinese type 2 diabetes mellitus (T2DM) patients recruited from 100 tier 2 or 3 hospitals, China.It is a drug intense monitoring study required by China Food and Drug Administration (CFDA) to assess the newly …

Phase N/A

0.0 miles

Learn More »

A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension

This is a multicentre clinical trial to evaluate safety and efficacy of renal denervation system in treatment of hypertension. Hypertensive patients who meet enrollment criteria will be randomized into treatment group who will receive standardized drugs and renal denervation treatments, or control group who will receive standardized drugs and a …

Phase N/A

0.0 miles

Learn More »

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Upon meeting the eligibility requirements and enrolling on study, Subjects will be collected large numbers of peripheral blood mononuclear cells (PBMC) for the generation of the CD19 CAR-T cells. The T cells are isolated from the PBMC, transduced with a lentivirus to express the CD19 CAR as well as a …

Phase

0.0 miles

Learn More »

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

This study is designed to evaluate the efficacy and safety of Pyrotinib in patients of advanced pre-treated Non-small cell lung cancer With HER2 Mutation. To observe objective response rate (ORR) of pyrotinib in NSCLC With HER2 Mutation. To observe Progression free survival (PFS). To assess the overall survival (OS). A …

Phase

0.0 miles

Learn More »

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma

Phase

0.0 miles

Learn More »

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

The purpose of this study is to evaluate of the clinical efficacy and safety of DLAAG protocol in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome with blast excess

Phase

0.0 miles

Learn More »

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants

It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Novel oral anticoagulants-NOACs (include rivaroxaban, apixaban, dabigatran and so on) have advantages of convenient use and no need of monitoring, compared with the traditional vitamin …

Phase N/A

0.0 miles

Learn More »